Physician profile
Michael L Rubalsky
NPI 1407473697
$4,183.45
in general payments reported to CMS, 2019-2025
33 companies · $1,505 in 2025
The $1,505 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $226 · 2022: $438 · 2023: $1,212 · 2024: $802 · 2025: $1,505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,519.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,519.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $611.14 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $599.68 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $481.38 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $450.13 | 2022-2025 | |
| Lilly USA, LLC | $351.55 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $286.78 | 2021-2025 | |
| Exact Sciences Corporation | $191.24 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $108.50 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $106.39 | 2023-2025 | Rexulti, Nuedexta |
| Amgen INC. | $93.63 | 2023-2024 | Repatha, Otezla |
| Lundbeck LLC | $83.35 | 2025 | Rexulti |
| Astellas Pharma US INC | $78.40 | 2023-2024 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.16 | 2022-2025 | Xifaxan |
| Ardelyx, INC. | $71.30 | 2024-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $64.20 | 2023-2024 | Gardasil 9, Capvaxive, Gardasil |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.67 | 2021-2025 | Jardiance, Ofev |
| Abbott Laboratories | $62.02 | 2021-2025 | Freestyle Libre 3 |
| Collegium Pharmaceutical, INC. | $48.59 | 2023 | Xtampza |
| Bayer Healthcare Pharmaceuticals INC. | $45.21 | 2022-2023 | |
| Lucid Diagnostics INC. | $37.23 | 2024 | |
| Inspire Medical Systems, INC. | $32.81 | 2024 | Inspire |
| Endo Pharmaceuticals INC. | $32.22 | 2021-2022 | |
| Gilead Sciences, INC. | $30.40 | 2022 | |
| Axsome Therapeutics, INC. | $28.48 | 2023 | Sunosi |
| Seqirus USA INC | $22.86 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Ironwood Pharmaceuticals, INC | $20.50 | 2022 | |
| Corcept Therapeutics | $19.66 | 2025 | Korlym |
| Biohaven Pharmaceutical Holding Company LTD. | $18.42 | 2022 | |
| Medtronic, INC. | $18.25 | 2024 | Minimed 780g |
| Kowa Pharmaceuticals America, INC. | $15.50 | 2025 | Zoryve |
| Janssen Pharmaceuticals, INC | $15.14 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $11.91 | 2021 | |
| Echosens North America, INC. | $7.75 | 2025 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Rubalsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.